Effects of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Using a Combination of Platinum Agents (Cisplatin plus Miriplatin): A Retrospective Comparison with Cisplatin Monotherapy
| Autor: | Satoshi Saitoh, Koichi Hamada, Noriyuki Nishino, Michitaka Honda, Yoshinori Horikawa, Shigeki Imai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cisplatin
medicine.medical_specialty Combination therapy business.industry Therapeutic effect Urology medicine.disease 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Hepatocellular carcinoma medicine Liver cancer Transcatheter arterial chemoembolization business Adverse effect medicine.drug |
| Zdroj: | Open Journal of Radiology. :260-273 |
| ISSN: | 2164-3032 2164-3024 |
| DOI: | 10.4236/ojrad.2018.84029 |
| Popis: | Background: Miriplatin is a slow-release, lipophilic platinum complex, developed to produce a superior antitumor effect for hepatocellular carcinoma (HCC). However, the miriplatin suspension is highly viscous and can form an embolism in the hepatic artery, which can result in insufficient antitumor effect. Thus, reducing the viscosity of the suspension compound by combining it with the less-viscous cisplatin suspension might reduce or even prevent vessel embolism, while providing the quick-release effects of cisplatin. Purpose: To compare the outcomes of therapy using miriplatin plus cisplatin and cisplatin monotherapy in transcatheter arterial chemoembolization (TACE) for HCC. Methods: We retrospectively evaluated a total of 87 patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B HCC who received conventional TACE using a combination of platinum agents (cisplatin and miriplatin) (n = 50) or cisplatin alone (n = 37) for the first time from September 2006 to December 2012. Short term therapeutic effect was measured by dynamic computed tomography 1 - 3 months after TACE, in reference to the modified Response Evaluation Criteria in Solid Tumors. Treatment-related adverse effects were graded by the National Cancer Institute Common Terminology Criteria (ver. 4.0). 1-, 3-, and 5-year survival rates were calculated. Subgroup analyses were performed by Child-Pugh classification and BCLC criteria. Results: Median duration of follow-up was 35 months (range 7 - 90). Median overall survival was 38 months. Patients who had combination therapy had better 1-, 3-, and 5-year survival rates: 100%, 56.7%, and 26.2%, respectively, compared to monotherapy: 100%, 42.1%, and 9.0%, respectively (p = 0.034). No serious complication or treatment-related mortality was observed in both groups. Conclusion: TACE using miriplatin plus cisplatin was related to a prolonged survival, with comparable adverse effects of TACE using cisplatin alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|